Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5916-5922

  Lepak, Alexander J ^a   Marchillo, Karen ^a   Pichereau, Solen ^a   Craig, William A ^a   Andes, David R ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; TEDIZOLID;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATE; BODY WEIGHT; COLONY FORMING UNIT; COMMUNITY; CONTROLLED STUDY; DISEASE MODEL; DRUG EXPOSURE; DRUG PROTEIN BINDING; FEEDING; HOSPITAL ACQUIRED PNEUMONIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STAPHYLOCOCCAL PNEUMONIA;

ACETAMIDES; ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BLOOD PROTEINS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; LUNG; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; ORGANOPHOSPHATES; OXAZOLES; OXAZOLIDINONES; PNEUMONIA, STAPHYLOCOCCAL; PRODRUGS; PROTEIN BINDING; STAPHYLOCOCCUS AUREUS;

EID: 84868015180     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01303-12     Document Type: Article

References (59)

1. Ambrose PG, et al. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79 - 86.
2. Andes D. 2003. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. 47:1179-1186.
3. Andes D, Craig WA. 1998. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 42:2375-2379.
4. Andes D, Craig WA. 2007. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob. Agents Chemother. 51:1633-1642.
5. Andes D, Craig WA. 2006. Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models. Antimicrob. Agents Chemother. 50:243-249.
6. Andes D, Craig WA. 2003. Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model. Antimicrob. Agents Chemother. 47:3935-3941.
7. Andes D, Craig WA. 2002. Pharmacodynamics of the new fluoroquin-olone gatifloxacin in murine thigh and lung infection models. Antimicrob. Agents Chemother. 46:1665-1670.
8. Andes D, van Ogtrop ML, Peng J, Craig WA. 2002. In vivo pharmaco-dynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46:3484-3489.
9. Betriu C, et al. 2010. Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain. Antimicrob. Agents Chemother. 54:2212-2215.
10. Bien P, et al. 2008. Human pharmacokinetics of TR-700 after ascending single oral doses of the prodrug TR-701, a novel oxazolidinone antibiotic, abstr F1-2063. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
11. Bien P, Prokocimer P, Munoz KA, Bethune C. 2010. Absolute bioavail-ability of TR-701 FA and pharmacokinetics after single and multiple dose intravenous administration in healthy adult subjects, abstr A1-013. Abstr. 50th Annu. Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA. American Society for Microbiology, Washington, DC.
12. Boselli E, et al. 2005. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit. Care Med. 33:1529-1533.
13. Boucher HW, Corey GR. 2008. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46(Suppl. 5):S344-S349.
14. Brown SD, Traczewski MM. 2010. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob. Agents Chemother. 54:2063-2069.
15. Clinical and Laboratory Standards Institute (CLSI). 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobi-cally; approved standards - eighth edition. CLSI document M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Conte JE, Jr, Golden JA, Kipps J, Zurlinden E. 2002. Intrapulmonary pharmacokinetics of linezolid. Antimicrob. Agents Chemother. 46:1475-1480.
17. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
18. Craig WA, Andes DR, Stamstad T. 2010. In vivo pharmacodynamics of new lipopeptide MX-2401. Antimicrob. Agents Chemother. 54:5092-5098.
19. David MZ, Daum RS. 2010. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin. Microbiol. Rev. 23:616-687.
20. Diekema DJ, et al. 2001. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2):S114-S132.
21. Drusano GL. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2:289-300.
22. Drusano GL, Liu W, Kulawy R, Louie A. 2011. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob. Agents Chemother. 55:5300-5305.
23. Gentry-Nielsen MJ, Olsen KM, Preheim LC. 2002. Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia. Antimicrob. Agents Chemother. 46:1345-1351.
24. Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R. 2003. Intrapul-monary penetration of linezolid. J. Antimicrob. Chemother. 51:1431-1434.
25. Hota B, et al. 2011. Predictors of clinical virulence in community-onset methicillin-resistant Staphylococcus aureus infections: the importance of USA300 and pneumonia. Clin. Infect. Dis. 53:757-765.
26. Housman ST, et al. 2012. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob. Agents Chemother. 56:2627-2634.
27. Keel RA, Tessier PR, Crandon JL, Nicolau DP. 2012. Comparative efficacy of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Antimicrob. Agents Chemother. 56:4403-4407.
28. Klein E, Smith DL, Laxminarayan R. 2007. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg. Infect. Dis. 13:1840-1846.
29. Klevens RM, et al. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771.
30. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. 2004. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. 30:388-394.
31. Kreienbuehl L, Charbonney E, Eggimann P. 2011. Community-acquired necrotizing pneumonia due to methicillin-sensitive Staphylococcus aureus secreting Panton-Valentine leukocidin: a review of case reports. Ann. Intensive Care 1:52. doi:10.1186/2110-5820-1-52.
32. Locke JB, Hilgers M, Shaw KJ. 2009. Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin. Antimicrob. Agents Chemother. 53:5275-5278.
33. Locke JB, Hilgers M, Shaw KJ. 2009. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxa-zolidinones linezolid and torezolid (TR-700). Antimicrob. Agents Chemother. 53:5265-5274.
34. Louie A, Liu W, Deziel MR, Drusano GL. 2004. Pharmacodynamics of linezolid in a neutropenic mouse thigh model of Staphylococcus aureus infection, abstr A-1805. Abstr. 44th Annu. Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
35. Louie A, Liu W, Kulawy R, Drusano GL. 2011. In vivo pharmacody-namics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in a mouse thigh infection model. Antimicrob. Agents Chemother. 55:3453-3460.
36. Luna CM, et al. 2009. Effect of linezolid compared with glycopeptides in methicillin-resistant Staphylococcus aureus severe pneumonia in piglets. Chest 135:1564-1571.
37. MacGowan AP. 2003. Pharmacokinetic and pharmacodynamic profile of linezolidinhealthy volunteers and patients with Gram-positive infections. J. Antimicrob. Chemother. 51(Suppl. 2):ii17-ii25.
38. Martinez-Olondris P, et al. 2012. Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin- resistant Staphylococcus aureus in ventilated pigs. Crit. Care Med. 40: 162-168.
39. Munoz KA, et al. 2010. Improved pharmacokinetics of the novel oxazo-lidinone antibiotic torezolid phosphate compared to linezolid in healthy subjects, abstr P-1594. 20th Eur. Cong. Clin. Microbiol. Infect. Dis., Vienna, Austria. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
40. Pfaller MA, et al. 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
41. Pfaller MA, Diekema DJ, Sheehan DJ. 2006. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19:435-447.
42. Prokocimer P, et al. 2008. Human pharmacokinetics of the prodrug TR-701 and TR-700, its active moiety, after multiple oral doses of TR-701, a novel oxazolidinone, abstr F1-2064. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
43. Prokocimer P, et al. 2011. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacoki-netics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob. Agents Chemother. 55:583-592.
44. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. 2003. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin. Pharmacokinet. 42: 1411-1423.
45. Rex JH, et al. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin. Infect. Dis. 24:235-247.
46. Rodriguez-Avial I, et al. 2012. In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci. J. Antimicrob. Chemother. 67: 167-169.
47. Safdar N, Andes D, Craig WA. 2004. In vivo pharmacodynamic activity of daptomycin. Antimicrob. Agents Chemother. 48:63-68.
48. Schaadt R, Sweeney D, Shinabarger D, Zurenko G. 2009. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob. Agents Chemother. 53:3236-3239.
49. Shaw KJ, et al. 2008. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob. Agents Chemother. 52:4442-4447.
50. Shorr AF, et al. 2006. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit. Care 10:R97. doi:10.1186/cc4934.
51. Slatter JG, et al. 2002. Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 32:907-924.
52. Stefani S, Varaldo PE. 2003. Epidemiology of methicillin-resistant staph-ylococci in Europe. Clin. Microbiol. Infect. 9:1179-1186.
53. Strukova EN, et al. 2009. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. Int. J. Antimicrob. Agents 33:251-254.
54. Styers D, Sheehan DJ, Hogan P, Sahm DF. 2006. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 statusin the United States. Ann. Clin. Microbiol. Antimicrob. 5:2. doi:10.1186/1476-0711-5-2.
55. Tessier PR, Keel RA, Hagihara M, Crandon JL, Nicolau DP. 2012. Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model. Antimicrob. Agents Chemother. 56:2342-2346.
56. Watanabe A, et al. 2012. Usefulness of linezolid in the treatment of hospital-acquired pneumonia caused by MRSA: a prospective observational study. J. Infect. Chemother. 18:160-168.
57. Wunderink RG, et al. 2012. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin. Infect. Dis. 54:621-629.
58. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. 2003. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124:1789-1797.
59. Yum JH, et al. 2010. Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea. Antimicrob. Agents Chemother. 54:5381-5386.